Lantern Pharma Showcases AI Innovations in Oncology and Upcoming Financial Webcast

Lantern Pharma Highlights AI-driven Advancements in Oncology

Lantern Pharma Inc., an innovative player in cancer therapy development, continues to make significant strides with its proprietary RADR® AI platform. The company announces plans to host a webcast on November 7, 2024, at 4:30 p.m. Eastern Time, where CEO Panna Sharma and the management team will provide an update on its third-quarter operating and financial results for the period ending September 30, 2024. This event underscores Lantern Pharma's commitment to transparency and engagement with stakeholders as it navigates the complexities of drug development in the oncology sector. The webcast will not only review financial performance but also highlight the progress of clinical trials and key upcoming milestones in the company's pipeline.

The RADR® platform is a cornerstone of Lantern Pharma's strategy, utilizing an extensive database of over 100 billion oncology-focused data points and advanced machine learning algorithms. This technology enables the company to address critical challenges in oncology drug development, significantly reducing the time and cost associated with bringing new therapies to market. According to Lantern, the average duration from initial AI-driven insights to first-in-human clinical trials is compressed to just 2-3 years, with costs ranging from $1 million to $2.5 million per program. This efficiency in drug development not only accelerates the timeline for potential breakthrough therapies but also positions Lantern Pharma as a leader in the integration of artificial intelligence in oncology.

Lantern Pharma is progressing on multiple fronts with its clinical pipeline. The company is advancing a Phase 2 program and several Phase 1 trials, while its subsidiary, Starlight Therapeutics, focuses on therapies for central nervous system and brain cancers. The combined annual market potential for these initiatives exceeds $15 billion, indicating the significant impact that successful therapies could have on the treatment landscape for cancer patients worldwide. By leveraging AI, Lantern Pharma aims to enhance patient care and deliver transformative treatment options, reaffirming its mission to revolutionize cancer therapy through innovative technology.

In addition to the webcast, Lantern Pharma remains dedicated to fostering open communication with investors and the public. Registration for the earnings call is available via a Zoom link, and a replay will be accessible on the company’s investor relations website afterwards. These efforts reflect the company’s proactive approach in keeping stakeholders informed about its developmental journey and ongoing projects in the oncology sector. As Lantern Pharma continues to harness the power of AI, it paves the way for advancements that could redefine cancer treatment paradigms.